A5100638261- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
- Medical Imaging Techniques and Applications
- Ferroptosis and cancer prognosis
- Ferroelectric and Piezoelectric Materials
- PI3K/AKT/mTOR signaling in cancer
- Radiopharmaceutical Chemistry and Applications
Seoul National University Hospital
2016-2025
Seoul National University
2016-2025
New Generation University College
2011-2025
National University College
2011-2023
Animal and Plant Quarantine Agency
2019
Samsung Medical Center
2017-2018
Guangdong General Hospital
2018
Guangdong Academy of Medical Sciences
2018
National Taiwan University Hospital
2018
Odense University Hospital
2017
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib patients previously untreated, advanced NSCLC, including those asymptomatic CNS disease.In randomized, open-label, phase 3 trial, we randomly assigned 303 NSCLC to receive either (600 mg twice daily) or (250 daily). The primary end point...
The selection and assembly of materials are central issues in the development smaller, more flexible batteries. Cobalt oxide has shown excellent electrochemical cycling properties is thus under consideration as an electrode for advanced lithium We used viruses to synthesize assemble nanowires cobalt at room temperature. By incorporating gold-binding peptides into filament coat, we formed hybrid gold–cobalt wires that improved battery capacity. Combining virus-templated synthesis peptide...
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy lorlatinib, as compared that crizotinib, first-line treatment for advanced NSCLC is unclear.
This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib.For 90 consecutive NSCLC who had received gefitinib, EGFR analyzed by DNA sequencing exons 18, 19, 21, 23 tyrosine kinase domain. Expressions phosphorylated (p) -Akt p-Erk were determined via immunohistochemistry. Response rate, time progression (TTP), overall compared...
Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) experience disease progression during treatment due to brain metastases. Despite anecdotal reports EGFR-TKIs providing benefit in some EGFRm NSCLC metastases, there is a clinical need for novel improved efficacy against lesions.We performed preclinical assessments penetration and activity osimertinib (AZD9291), an oral, potent,...
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods were stratified by brain metastases best response to crizotinib. They randomly assigned (1:1) oral brigatinib 90 mg once daily (arm A) or 180 a 7-day...
NK cell function in cancer patients is severely impaired, but the mechanism underlying this impairment not clearly understood. In study we show evidence that TGF-beta1 secreted by tumors responsible for poor lytic activity via down-regulating an NK-activating receptor, NKG2D. The plasma level of human lung or colorectal was elevated compared with normal volunteers, and elevation inversely correlated surface expression NKG2D on cells these patients. Incubation obtained from specifically...
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody immune cell-directing activity, binds each receptor's extracellular domain, bypassing at the inhibitor binding site.CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included population EGFR Exon20ins NSCLC. The primary end...
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety osimertinib (an epidermal growth factor receptor [EGFR] –tyrosine kinase inhibitor selective for EGFR–tyrosine sensitizing [ EGFRm] EGFR T790M resistance mutations) as first-line treatment EGFR-mutated advanced non–small-cell lung cancer (NSCLC). Patients Methods Sixty with locally or metastatic EGFRm NSCLC received 80 160 mg once daily...
Purpose Approximately 1% to 2% of non-small-cell lung cancers (NSCLCs) harbor a c-ros oncogene 1 ( ROS1) rearrangement. Crizotinib, an inhibitor anaplastic lymphoma kinase (ALK), ROS1, and MET, has shown marked antitumor activity in small expansion cohort patients with ROS1-positive advanced NSCLC from ongoing phase I study. We assessed the efficacy safety crizotinib largest NSCLC. Patients Methods This II, open-label, single-arm trial enrolled East Asian (assessed through validated AmoyDx...
Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study ALK-positive non–small-cell lung cancer. Patients and Methods were randomly assigned to receive (250 mg twice daily; n = 172) or (pemetrexed 500 mg/m 2 plus cisplatin 75 carboplatin at area under curve 5 6, every 3 weeks for ≤ six cycles; 171). with stable treated brain metastases (tBM) eligible. assessed baseline 6 12 patients without known (BM),...
There is currently no reliable biomarker to predict who would benefit from anti-PD-1/PD-L1 inhibitors. We comprehensively analyzed the immunogenomic properties in The Cancer Genome Atlas (TCGA) according classification of tumor into four groups based on PD-L1 status and tumor-infiltrating lymphocyte recruitment (TIL), a combination that has been suggested be theoretically inhibitors.The RNA expression levels CD8A samples pan-cancer database TCGA (N = 9,677) were analyzed. Based their median...
AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment EGFR TKIs. However, acquired resistance to AZD9291 inevitable. In this study, we identified the mechanisms of in NSCLC.Four NSCLC both an exon 19 deletion mutation after developing first-generation TKIs received at doses 20 80 mg/day phase I trial (NCT01802632)....
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but not a known mechanism of resistance to EGFR inhibitors. HER3-DXd an antibody-drug conjugate consisting HER3 antibody attached topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic non-small cell cancer (NSCLC) prior tyrosine (TKI) therapy. Among 57 receiving 5.6 mg/kg...
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd has not been evaluated patients with previously treated human epidermal growth factor receptor 2-mutant (
Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to epidermal growth factor receptor 3 (HER3) attached topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety HER3-DXd in patients with (
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.In longest follow-up, our knowledge, a KRASG12C inhibitor, we assessed long-term efficacy, safety, and biomarkers of...
PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) the phase III CROWN study. Here, we report long-term outcomes from after 5 years of follow-up. METHODS Two hundred ninety-six NSCLC were randomly assigned 1:1 to receive lorlatinib 100 mg once daily (n = 149) or 250 twice 147). This post hoc analysis presents updated investigator-assessed...